Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis
The aim of the study is to evaluate the efficacy of Baricitinib, a JAK1 and 2 inhibitor, in the management of non-infectious non-anterior uveitis refractory to at least one line of biotherapy (anti-TNF alpha, tocilizumab) after 6 months of treatment
Patient with diagnosis of non-anterior non-infectious uveitis, refractory to at... [+1]
1. Isolated anterior uveitis. 2. Infectious uveitis. 3. Severe uveitis threateni...